SCIENTIFIC OPINION

Scientific Opinion on the substantiation of health claims related to phaseolamine and reduction in body weight (ID 1701) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

European Food Safety Authority (EFSA), Parma, Italy

SUMMARY

Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims in relation to phaseolamine and reduction in body weight. The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.

The food constituent that is the subject of the health claim is phaseolamine. The Panel considers that phaseolamine is sufficiently characterised in relation to the claimed effect.

The claimed effect is “inhibit $\alpha$-amylase activity, hindering the conversion of complex carbohydrate to simple sugars, which are stored as reservoir fats if not immediately utilised by the organism; it results in a lower calories intake, contributing to weight loss”. The target population is assumed to be overweight individuals in the general population who wish to reduce their body weight. In the context of the proposed wordings, the Panel assumes that the claimed effect refers to a reduction in body weight. The Panel considers that reduction in body weight is a beneficial physiological effect.

In weighing the evidence, the Panel took into account that although one short-term (30 day) intervention study in humans showed an effect of phaseolamine consumption on reduction in body weight, a second human intervention study, using higher phaseolamine doses and of longer duration (eight weeks), did not show an effect of phaseolamine consumption on body weight changes at any time point considered.

---

1 On request from the European Commission, Question No EFSA-Q-2008-2437, adopted on 25 March 2011.
2 Panel members: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Lovik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhausser-Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen. Correspondence: nda@efsa.europa.eu
3 Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the Working Group on Claims: Carlo Agostoni, Jean-Louis Bresson, Susan Fairweather-Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Lovik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub-Working Group on Weight Management/Satiety/ Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette Hansen, Mette Kristensen, Anders Sjödin and Inge Tetens.


© European Food Safety Authority, 2011
On the basis of the data presented, the Panel concludes that a cause and effect relationship has not been established between the consumption of phaseolamine and reduction in body weight.

**KEY WORDS**

Phaseolamine, body weight, health claims.
TABLE OF CONTENTS

Summary .............................................................................................................................................. 1
Table of contents ................................................................................................................................. 3
Background as provided by the European Commission ........................................................................ 4
Terms of reference as provided by the European Commission ............................................................ 4
EFSA Disclaimer ................................................................................................................................... 4
Information as provided in the consolidated list ................................................................................... 5
Assessment ........................................................................................................................................... 5
  1. Characterisation of the food/constituent (ID 1701) ........................................................................ 5
  2. Relevance of the claimed effect to human health (ID 1701) ......................................................... 5
  3. Scientific substantiation of the claimed effect (ID 1701) ............................................................... 5
Conclusions .......................................................................................................................................... 6
Documentation provided to EFSA ......................................................................................................... 7
References ............................................................................................................................................ 7
Appendices .......................................................................................................................................... 8
BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
See Appendix A

TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
See Appendix A

EFSA DISCLAIMER
See Appendix B
INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST

The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 submitted by Member States contains main entry claims with corresponding conditions of use and literature for similar health claims. EFSA has screened all health claims contained in the original consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria established by the NDA Panel to identify claims for which EFSA considered sufficient information had been provided for evaluation and those for which more information or clarification was needed before evaluation could be carried out. The clarifications which were received by EFSA through the screening process have been included in the consolidated list. This additional information will serve as clarification to the originally provided information. The information provided in the consolidated list for the health claims which are the subject of this opinion is tabulated in Appendix C.

ASSESSMENT

1. Characterisation of the food/constituent (ID 1701)

The food constituent that is the subject of the health claim is phaseolamine.

Phaseolamine is a generic name for a proteinaceous inhibitor of animal alpha-amylases that is obtained from kidney beans (Phaseolus vulgaris L.) and which can be purified to homogeneity by conventional protein fractionation methods (Marshall and Lauda, 1975). Different extracts standardised by their in vitro alpha-amylase inhibitory activity exist on the market.

The Panel considers that the food constituent, phaseolamine, which is the subject of the health claim, is sufficiently characterised in relation to the claimed effect.

2. Relevance of the claimed effect to human health (ID 1701)

The claimed effect is “inhibit α-amylase activity, hindering the conversion of complex carbohydrate to simple sugars, which are stored as reservoir fats if not immediately utilised by the organism; it results in a lower calories intake, contributing to weight loss”. The Panel assumes that the target population is overweight individuals in the general population who wish to reduce their body weight.

In the context of the proposed wordings, the Panel assumes that the claimed effect refers to reduction in body weight.

Weight loss can be interpreted as the achievement of a normal body weight in previously overweight subjects. In this context, weight loss in overweight subjects without the achievement of a normal body weight is considered to be a beneficial physiological effect.

The Panel considers that reduction in body weight is a beneficial physiological effect.

3. Scientific substantiation of the claimed effect (ID 1701)

The references provided for the scientific substantiation of the claim included human studies which reported on health outcomes unrelated to the claimed effect (e.g. post-prandial blood glucose

---


Phaseolamine and reduction in body weight

responses), and a study on the extraction process and purification of phaseolamine. The Panel considers that no conclusions can be drawn from these references for the scientific substantiation of the claim.

An open label, one arm human intervention study which investigated the effects of consuming a food supplement containing 750 mg phaseolamine per capsule (three capsules twice daily) for eight weeks on body weight in 10 overweight subjects was provided (Koike et al., 2005). The Panel considers that no conclusions can be drawn from this uncontrolled study for the scientific substantiation of the claim.

In a randomised, placebo-controlled, human intervention study (Udani et al., 2004), 39 obese subjects (4 males, age range 20-69 years) were randomly allocated to consume 1,500 mg of a water extract from *Phaseolus vulgaris* L. (phaseolamine, n=20) or placebo (n=19) twice daily at lunch or dinner for eight weeks in the context of a “low-fat/high fibre” diet providing 100-200 g of complex carbohydrates mainly at the main meals. A total of 27 subjects completed the study. Data analysis was intention-to-treat. Body weight was assessed at weeks 2, 4, 6 and 8 of the study. No significant differences in body weight changes between groups were observed during the study at any time point. The Panel notes that consumption of phaseolamine did not lead to a significant reduction in body weight compared to placebo in this study.

In a second randomised, placebo-controlled, human intervention study (Celleno et al., 2007), 60 overweight subjects were randomly allocated to consume an 800 mg tablet containing 445 mg of a dried water extract from *Phaseolus vulgaris* L. (phaseolamine) standardised to a minimum of 3,000 alpha-amylase inhibiting units (n=30) or placebo (microcrystalline cellulose and maltodextrin, n=30) once daily before the main, carbohydrate-rich, meal for 30 days, after a two-week run-in phase in which all subjects received placebo. Dietary recommendations were provided to all subjects, and these recommendations included a daily intake of complex carbohydrates concentrated in one or two meals. The study diet provided 2000-2200 kcal/day. A total of 59 subjects (29 controls) completed the study and entered data analysis. A significant reduction in body weight was observed in the intervention group (-2.93±1.16 kg) compared to placebo (-0.35±0.38 kg, p<0.001). The Panel notes the short duration of the study.

*In vitro* studies which investigated the effects of phaseolamine on amylase activity and starch digestion were also provided. The Panel considers that evidence provided in *in vitro* studies is not sufficient to predict an effect of phaesolamine on starch ingestion *in vivo* in humans.

In weighing the evidence, the Panel took into account that although one short-term (30 day) intervention study in humans showed an effect of phaseolamine consumption on reduction in body weight, a second human intervention study using higher phaseolamine doses and of longer duration (eight weeks), did not show an effect of phaseolamine consumption on body weight changes at any time point considered.

The Panel concludes that a cause and effect relationship has not been established between the consumption of phaseolamine and reduction in body weight.

**CONCLUSIONS**

On the basis of the data presented, the Panel concludes that:

- The food constituent, phaseolamine, which is the subject of the health claim, is sufficiently characterised in relation to the claimed effect.
The claimed effect is “inhibit α-amylase activity, hindering the conversion of complex carbohydrate to simple sugars, which are stored as reservoir fats if not immediately utilized by the organism; it results in a lower calories intake, contributing to weight loss”. The target population is assumed to be overweight individuals in the general population who wish to reduce their body weight. Reduction in body weight is a beneficial physiological effect.

A cause and effect relationship has not been established between the consumption of phaseolamine and reduction in body weight.

**DOCUMENTATION PROVIDED TO EFSA**

Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-2437). The scientific substantiation is based on the information provided by the Member States in the consolidated list of Article 13 health claims and references that EFSA has received from Member States or directly from stakeholders.


**REFERENCES**


Phaseolamine and reduction in body weight

APPENDICES

APPENDIX A

BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION

The Regulation 1924/2006 on nutrition and health claims made on foods (hereinafter "the Regulation") entered into force on 19th January 2007.

Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted health claims other than those referring to the reduction of disease risk and to children's development and health. This Community list shall be adopted through the Regulatory Committee procedure and following consultation of the European Food Safety Authority (EFSA).

Health claims are defined as "any claim that states, suggests or implies that a relationship exists between a food category, a food or one of its constituents and health".

In accordance with Article 13 (1) health claims other than those referring to the reduction of disease risk and to children's development and health are health claims describing or referring to:

a) the role of a nutrient or other substance in growth, development and the functions of the body; or

b) psychological and behavioural functions; or

c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the sense of hunger or an increase in the sense of satiety or to the reduction of the available energy from the diet.

To be included in the Community list of permitted health claims, the claims shall be:

(i) based on generally accepted scientific evidence; and

(ii) well understood by the average consumer.

Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 January 2008 accompanied by the conditions applying to them and by references to the relevant scientific justification. These lists have been consolidated into the list which forms the basis for the EFSA consultation in accordance with Article 13 (3).

ISSUES THAT NEED TO BE CONSIDERED

IMPORTANCE AND PERTINENCE OF THE FOOD

Foods are commonly involved in many different functions of the body, and for one single food many health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for functions affected by a large number of dietary factors it should be considered whether a reference to a single food is scientifically pertinent.

---

6 OJ L12, 18/01/2007
7 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.
8 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).
It should also be considered if the information on the characteristics of the food contains aspects pertinent to the beneficial effect.

**SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE**

Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims should be scientifically substantiated by taking into account the totality of the available scientific data, and by weighing the evidence, and shall demonstrate the extent to which:

(a) the claimed effect of the food is beneficial for human health,

(b) a cause and effect relationship is established between consumption of the food and the claimed effect in humans (such as: the strength, consistency, specificity, dose-response, and biological plausibility of the relationship),

(c) the quantity of the food and pattern of consumption required to obtain the claimed effect could reasonably be achieved as part of a balanced diet,

(d) the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.

EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of the application for authorisation of health claims consistent criteria for the potential sources of scientific data. Such sources may not be available for all health claims. Nevertheless it will be relevant and important that EFSA comments on the availability and quality of such data in order to allow the regulator to judge and make a risk management decision about the acceptability of health claims included in the submitted list.

The scientific evidence about the role of a food on a nutritional or physiological function is not enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially affect identified functions in the body in a way which is relevant to health. Although an appreciation of the beneficial effect in relation to the nutritional status of the European population may be of interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or physiological effect for that population should not, however, condition such considerations.

Different types of effects can be claimed. Claims referring to the maintenance of a function may be distinct from claims referring to the improvement of a function. EFSA may wish to comment whether such different claims comply with the criteria laid down in the Regulation.

**WORDING OF HEALTH CLAIMS**

Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. However, the wording of health claims should also be commented by EFSA in its opinion.

There is potentially a plethora of expressions that may be used to convey the relationship between the food and the function. This may be due to commercial practices, consumer perception and linguistic or cultural differences across the EU. Nevertheless, the wording used to make health claims should be truthful, clear, reliable and useful to the consumer in choosing a healthy diet.

In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or other substance in growth, development and the functions of the body". Therefore, the requirement to
describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of the body should be carefully considered.

The specificity of the wording is very important. Health claims such as "Substance X supports the function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the various functions of the joints is described or referred to contrary to the latter example which specifies this by using the word "flexibility".

The clarity of the wording is very important. The guiding principle should be that the description or reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore be specified to the extent possible i.e. descriptive words/terms which can have multiple meanings should be avoided. To this end, wordings like "strengthens your natural defences" or "contain antioxidants" should be considered as well as "may" or "might" as opposed to words like "contributes", "aids" or "helps".

In addition, for functions affected by a large number of dietary factors it should be considered whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the strength of the scientific evidence.

Similar alternative wordings as mentioned above are used for claims relating to different relationships between the various foods and health. It is not the intention of the regulator to adopt a detailed and rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is not required that EFSA comments on each individual wording for each claim unless the wording is strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and comment generally on such elements relating to wording to ensure the compliance with the criteria laid down in the Regulation.

In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average consumer should be recalled. In addition, such assessment should take into account the particular perspective and/or knowledge in the target group of the claim, if such is indicated or implied.

**TERMS OF REFERENCE**

**HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO CHILDREN'S DEVELOPMENT AND HEALTH**

EFSA should in particular consider, and provide advice on the following aspects:

- Whether adequate information is provided on the characteristics of the food pertinent to the beneficial effect.
- Whether the beneficial effect of the food on the function is substantiated by generally accepted scientific evidence by taking into account the totality of the available scientific data, and by weighing the evidence. In this context EFSA is invited to comment on the nature and quality of the totality of the evidence provided according to consistent criteria.
- The specific importance of the food for the claimed effect. For functions affected by a large number of dietary factors whether a reference to a single food is scientifically pertinent.

In addition, EFSA should consider the claimed effect on the function, and provide advice on the extent to which:

- the claimed effect of the food in the identified function is beneficial.
- a cause and effect relationship has been established between consumption of the food and the claimed effect in humans and whether the magnitude of the effect is related to the quantity
consumed.

- where appropriate, the effect on the function is significant in relation to the quantity of the food proposed to be consumed and if this quantity could reasonably be consumed as part of a balanced diet.
- the specific study group(s) in which the evidence was obtained is representative of the target population for which the claim is intended.
- the wordings used to express the claimed effect reflect the scientific evidence and complies with the criteria laid down in the Regulation.

When considering these elements EFSA should also provide advice, when appropriate:

- on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides for additional labelling requirements addressed to persons who should avoid using the food; and/or warnings for products that are likely to present a health risk if consumed to excess.
APPENDIX B

EFSA DISCLAIMER

The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing of the food/food constituent, a positive assessment of its safety, nor a decision on whether the food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment is not foreseen in the framework of Regulation (EC) No 1924/2006.

It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of use as proposed in the Consolidated List may be subject to changes, pending the outcome of the authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006.
**APPENDIX C**

Table 1. Main entry health claims related to phaseolamine, including conditions of use from similar claims, as proposed in the Consolidated List.

<table>
<thead>
<tr>
<th>ID</th>
<th>Food or Food constituent</th>
<th>Health Relationship</th>
<th>Proposed wording</th>
</tr>
</thead>
<tbody>
<tr>
<td>1701</td>
<td>Phaseolamine (proteina concentrata di fagiolo Phaseolus vulgaris). Clarification provided Phaseolamine (bean's protein concentrated - Phaseolus vulgaris).</td>
<td>Inibisce l’attività dell’enzima α-amilasi, ostacolando in tal modo la trasformazione dei carboidrati complessi in zuccheri semplici, i quali vengono immagazzinati come grassi di deposito se non utilizzati subito dall’organismo. Ne risulta una diminuzione delle calorie assorbite con conseguente perdita di peso. Clarification provided Inhibit α-amylase activity, hindering the conversion of complex carbohydrate to simple sugars, which are stored as reservoir fats if not immediately utilized by the organism. It result in a lower calories intake, contributing to weight loss.</td>
<td>Con proteina concentrata di fagiolo che AIUTA A DIMAGRIRE. Clarification provided With concentrated bean proteins, which contributes to weight reduction.</td>
</tr>
</tbody>
</table>

**Conditions of use**
- Aggiunta ad un mix a base di farina per pane.